With biotech firms caught in the crosshairs of Trump's tariffs, the levy could prove to be a boon for domestic producers but ...

Capital is following suit, with dollars pouring into Chinese biotech assets, responding to a regulatory environment that’s more permissive of experimentation and progress. This is not theoretical.

The China Biotechnology Directory 2025 is an indispensable resource for navigating the fast-growing Chinese biotech market. With thousands of up-to-date company profiles, executive contacts, and ...

The global expansion of Chinese biotech companies accelerated in the first quarter, with the number of overseas deals surging 18 per cent year on year, showing strong momentum in the field of ...

Last month, Lilly's newly opened Lilly Gateway Labs in Beijing welcomed its first tenant, namely a Chinese biotechnology company focusing on innovative medicines for neurodegenerative and ...

The severe ESG risk rating is consistent with Chinese biotech company ratings on Sustainalytics. The risks are primarily from product governance and regulatory uncertainties. We assign Innovent an ...

China is moving fast to dominate biotechnology, and the U.S. risks ... in the U.S., while barring companies from working with Chinese biotech suppliers, the National Security Commission on ...

Akeso's drug sales rose 25% last year to just above 2 billion yuan, setting a new high for the company A potential launch for the company's ivonescimab in the U.S. next year could bring it big new ...

The China-US trade war has spread to the biotech industry, as the US BIOSECURE Act looks to dampen Chinese influence on a range of services, including contract manufacturing. Ben Hargreaves ...

Chinese biotech firm Duality Biotherapeutics launched an initial public offering (IPO) of up to HK$1.56 billion ($200.7 million) on Monday in Hong Kong, testing investor appetite amid a global stock ...